IL15 and neoplasm: To test whether NK cell activation could be a useful therapeutic approach to complement immunotherapy, Cish−/− mice, which downregulate negative feedback to IL-15 and thus enhance NK activity, were tested for their response to anti-PD-1 antibody compared to Cish + /+ mice, demonstrating better tumour control than the latter [99].